Articles tagged with: ACOR

Acorda Therapeutics had a not so very good Wednesday morning with NASDAQ halting their trading on the stock market as the review by the Food and Drug Administration panel was due.

It was not a good start for Acorda Therapeutics on Wednesday morning when NASDAQ decided to halt the trading of Acorda Therapeutics shares until the experts have voted on Acorda’s new MS drug.

It was a bad news for Acorda Therapeutics when they heard the news that NASDAQ has halted their trading and shares of Acorda Therapeutics were 18 percent down on the stock market.

It was a not a good closing day for Acorda Therapeutics when shares of its company went down drastically after the negative review by the Food and Drug Administration panel.

Acorda Therapeutics is very excited and waiting anxiously for the review of their new drug Amaya by the Food and Drug Administration advisory committee. Acorda’s new Amaya drug is targeted for the treatment of multiple …